Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

Core Insights - Pfizer announced its intention to acquire Metsera, a weight-loss drug developer, for up to $4.9 billion, aiming to strengthen its position in the obesity treatment market [1] Company Summary - The acquisition of Metsera is part of Pfizer's strategy to enhance its portfolio in the lucrative obesity treatment sector [1] Industry Summary - The obesity treatment market is characterized as lucrative, indicating significant growth potential and demand for effective weight-loss solutions [1]